PerspectiveTargeting of a common receptor shared by CXCL8 and N-Ac-PGP as a therapeutic strategy to alleviate chronic neutrophilic lung diseases
Research Highlights
► Persistent neutrophilia is implicated in the pathology of chronic lung diseases. ► Collagen-derived tripeptide, Pro-Gly-Pro (PGP), is a neutrophil chemoattractant. ► PGP is observed in chronic lung diseases such as COPD. ► PGP signals through CXCR1/2, the same receptors used by neutrophil chemokine CXCL8. ► Targeting shared receptors CXCR1/2 may alleviate neutrophilic inflammation.
Section snippets
Acknowledgements
RJS is supported by The Wellcome Trust (082727/Z/07/Z).
References (45)
- et al.
Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease
Am. J. Respir. Crit. Care Med.
(2001) - et al.
Hit-to-lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists
Bioorg. Med. Chem. Lett.
(2006) - et al.
Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4
Chest
(2003) Store-operated channels: diversity and activation mechanisms
Sci. STKE
(2004)- et al.
Cigarette smoke-induced lung emphysema in mice is associated with prolyl endopeptidase, an enzyme involved in collagen breakdown
Am. J. Physiol. Lung Cell. Mol. Physiol.
(2011) - et al.
CXCR2 antagonists block the N-Ac-PGP-induced neutrophil influx in the airways of mice, but not the production of the chemokine CXCL1
Eur. J. Pharmacol.
(2011) - et al.
CXCR2 antagonists for the treatment of pulmonary disease
Pharmacol. Ther.
(2009) - et al.
Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids
J. Biol. Chem.
(1994) - et al.
Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4
Eur. Respir. J.
(2000) - et al.
The collagen-breakdown product N-acetyl-Proline-Glycine-Proline (N-alpha-PGP) does not interact directly with human CXCR1 and CXCR2
Eur. J. Pharmacol.
(2010)
Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies
Pharmacol. Ther.
A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation
J. Immunol.
Bioactivity of peptide analogs of the neutrophil chemoattractant, N-acetyl-proline-glycine-proline
Invest. Ophthalmol. Vis. Sci.
The presence of a matrix-derived neutrophil chemoattractant in bronchiolitis obliterans syndrome after lung transplantation
J. Immunol.
SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects
Eur Respir J
A CXCL8 receptor antagonist based on the structure of N-acetyl-proline-glycine-proline
Eur. J. Pharmacol.
Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma
Am. J. Respir. Crit. Care Med.
Activation of CXCR2 by extracellular matrix degradation product acetylated-pro-gly-pro has therapeutic effects against sepsis
Am. J. Respir. Crit. Care Med.
Chemokines — chemotactic cytokines that mediate inflammation
N. Engl. J. Med.
The molecular biology of leukocyte chemoattractant receptors
Annu. Rev. Immunol.
Inflammatory cells in the airways in COPD
Thorax
N-alpha-PGP and PGP, potential biomarkers and therapeutic targets for COPD
Respir. Res.
Cited by (19)
Constitutively active chemokine CXC receptors
2014, Advances in PharmacologyCitation Excerpt :Excessive inflammation caused by the recruited neutrophils is thought, at least partially, to be responsible for COPD, asthma, inflammatory bowel diseases, and Crohn's disease. Hence, targeting CXCR1 using structural and biochemical approaches to develop specific antagonists is a promising therapeutic strategy to modulate the receptor activity to combat these diseases (Bizzarri et al., 2006; Panina, Mariani, & D'Ambrosio, 2006; Snelgrove, 2011). Additionally, CXCR1 promotes IL-8-mediated tumor growth such as prostate cancer (Shamaladevi, Lyn, Escudero, & Lokeshwar, 2009), breast cancer (Ginestier et al., 2010), colorectal cancer, and melanoma (Sharma, Singh, Varney, & Singh, 2010), and the CXCR1 blockade provides a possible therapeutic intervention point in targeting the tumor microenvironment.
New treatments for COPD
2013, Current Opinion in PharmacologyCitation Excerpt :ADZ8309, an oral CXCR1/2 antagonist inhibits neutrophilic inflammation [36]. In addition the CXCR2 antagonists SB-656933 and SCH-527123 are also currently being evaluated in clinical trials [37]. There is a growing interest in the potential role of the innate immune system particularly TLRs in COPD pathogenesis [4].
Effect of Modified Erchentang on Expressions of Chemokine Receptor CXCR1/2 and CXCL8 in Patients with AECOPD
2019, Chinese Journal of Experimental Traditional Medical FormulaeGlyprolines as modulators of immunoreactivity within conditions of "social" stress
2019, Farmatsiya i Farmakologiya